ZymoGenetics (ZGEN) Announces Merck Serono to Discontinue Study in Lupus Nephritis in Ongiong Phase II/III Trials

October 27, 2008 10:18 AM EDT Send to a Friend
Get Alerts ZGEN Hot Sheet
Trade ZGEN Now!
Join SI Premium – FREE
In a Form 8-K, ZymoGenetics (Nasdaq: ZGEN) announced that on October 27, Merck Serono announced that it was discontinuing the study in lupus nephritis in the ongoing Phase II/III systemic lupus erythematosus atacicept program. The study combining mycophenolate mofetil, corticosteroids and atacicept in patients with kidney disease had been initiated in December 2007. The observation of an increased risk for severe infection led to the discontinuation. This observation was likely the result of the underlying significant disease activity and the concomitant use of several immunosuppressive medications. The ongoing atacicept programs in generalized SLE, rheumatoid arthritis, multiple sclerosis and hematological malignancies are continuing.

ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases primarily hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections.

You May Also Be Interested In





Related Categories

Corporate News

Add Your Comment